Paclitaxel and its formulations.
By A. K. Singla, A. Garg, Deepika Aggarwal. International journal of pharmaceutics, 2002
1,030 citations recorded by the source corpus.
Subfields: Dermatology, Oncology
View Paper: https://www.semanticscholar.org/paper/0de9a0350145bbf25eb87d79c4c98962ef69f8de
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Dermatology
In Oncology
- Colin W. Pouton
- L. Brannon-Peppas
- Shuming Nie
- Olivier Féron
- J. Blanchette
- V. Préat
- F. Danhier
- D. McClements
Citations in the corpus
- Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. (2009, background): “PTX is approved in many countries for its use as second line treatment of ovarian and breast cancers [ 1 ,2] .P TX has a uniquemechanismofaction.Itdisruptsthedynamicequilibriumwithin the microtubule system and blocks cells in the late G2 phase and M phase of the cell cycle, thereby inhibiting cell r”
- Cyclodextrins in drug delivery: An updated review (2005, positive): “The inclusion ability of DM-β-CD, causing the release of the transporters (P-gp, MRP2) from the apical membranes of monolayers, was reported to be the possible reason for the observed impaired efflux function of the transporters in the presence of the CD.”
- Nanoparticle and targeted systems for cancer therapy. (2004, methodology): “The currently available formulation includes Chremophor EL (polyethoxylated castor oil) and ethanol for solubilization however Chremophor EL is toxic and shows side effects such as hypersensitivity reactions, nephrotoxicity and neurotoxicity [24].”
- Strategies to Address Low Drug Solubility in Discovery and Development (2013, background): “…pharmacological effects of the formulation components are limited, in the case of surfactants increasing evidence suggests the potential for inhibitory effects on both metabolic and drug transport or antitransport processes (Martin-Facklam et al., 2002b; Singla et al., 2002; Bogman et al., 2003).”
- Nanotechnology applications in cancer. (2007, methodology): “Because it is poorly soluble in aqueous solution, the formulation available currently is Chremophor EL (polyethoxylated castor oil) and ethanol (126).”